Propionic Acidemia Market size is expected to reach USD 45 Billion by the end of 2036, growing at a CAGR of 4% during the forecast period i.e., 2024-2036. In the year 2023, industry size of propionic acidemia was USD 2 Billion. One important factor that will help the market to grow over the forecast period is an increase in prevalence of propionic acidemia. For instance, according to the article published in NCBI Propionic acidemia affects about 1 in 100,000 people in the United States. In some populations, such as Greenland's Inuit population and certain amish communities in Saudi Arabia, the condition seems to be more common. Moreover, propionic acidemia market growth will also be driven by an increasing number of treatment options and a rise in the incidence of ketotic hyperglycaemia and others.
The efficacy and patient compliance of the treatment is enhanced by technological advances in drug delivery systems and formulation. In addition, improved access to healthcare for patients with uncommon diseases such as propionic acidemia is facilitated by the growing use of telemedicine and Digital Health Platforms.
Growth Drivers
Challenges
|
Base Year |
2023 |
|
Forecast Year |
2024 - 2036 |
|
CAGR |
~4% |
|
Base Year Market Size (2023) |
~USD 2 Billion |
|
Forecast Year Market Size (2036) |
~USD 45 Billion |
|
Regional Scope |
|
Drug Class (L-Carnitine, Antibiotics)
In terms of drug class, L-carnitine segment is estimated to hold 70% share of the global propionic acidemia market by 2036. L-carnitine is a chemical that's produced in the human brain, liver and kidneys. It's helping the body to make energy out of fat. L-carnitine is a vital element for the health of the heart and brain, muscle activity as well as many different processes in the body. The body is capable of converting L-carnitine into other chemicals called acetylcarnitine, and propionyl. In three patients with Propionic Acidemia and in 3 standard controls, L-Carnitine significantly increased the formation and excretion of short chain acylcarnitine. Acylcarnitine has been found to be propionylcarnitine in patients with proionic acidemia by the use of rapid atom bombardment mass spectrometry and a correlation scan at constant magnet-to-electric field ratio. Mostly acetylcarnitine was absorbed by the normal children.
Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
Based on distribution channel, the retail pharmacy segment is expected to hold a notable share of the global propionic acidemia market by 2036. When patients are discharged from hospital, retail pharmacies play an important role in supplying them with medicinal products. Retail pharmacies offer convenient access to essential medications such as carnitine supplements, vitamins and antibiotics for managing PA symptoms. This can be particularly beneficial for patients in remote areas or those who struggle with transportation to specialized clinics. Retail chains are the biggest and most predominant of the four drug store sorts, speaking to a third of stores and around a third of medicine incomes in 2021.
Our in-depth analysis of the global market includes the following segments:
|
Drug Class |
|
|
Route of Administration |
|
|
Distribution Channel |
|
North American Market Forecasts
The propionic acidemia market in the North America region is set to hold the highest CAGR of 35% by the end of 2036. This growth can be attributed to improved healthcare infrastructure, FDA approvals, increased prevalence of propionic acidemia, collaboration and acquisitions with key players and others expected to dominate this region during the forecast period. For example, an orphan drug designation for AAV9hPCCA for the treatment of propionic acidemia was granted by the FDA to the National Center for Advancing Translational Sciences in May 2022.
APAC Market Statistics
The propionic acidemia market in the Asia Pacific region is set to grow significantly during the time period between 2024-2036. Newborn screening programs are essential for early diagnosis of propionic acidemia, as early intervention can significantly enhance patient outcomes. The adoption of newborn screening programs is increasing in the Asia Pacific region, which is anticipated to lead toa rise in diagnosed cases of propionic acidemia and consequently the propionic acidemia market.
Author Credits: Rajrani Baghel
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?